Detalle Publicación

Psoriasiform exfoliative erythroderma induced by golimumab

Autores: Mateo, S. (Autor de correspondencia); García Martinez, Francisco Javier; Sánchez-Aguilar, D.; Amarelo, J.; Toribio, J.
Título de la revista: CLINICAL AND EXPERIMENTAL DERMATOLOGY
ISSN: 0307-6938
Volumen: 39
Número: 7
Páginas: 813 - 815
Fecha de publicación: 2014
Resumen:
Golimumab is a fully human anti-tumour necrosis factor (TNF)- monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti-TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.
DOI: https://doi.org/10.1111/ced.12402
Impacto:
6 citas en
Google Scholar